Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease

Simple item page
dc.contributor.authorKremer, Thomas
dc.contributor.authorTaylor, Kirsten I.
dc.contributor.authorSiebourg-Polster, Juliane
dc.contributor.authorGerken, Thomas
dc.contributor.authorStaempfli, Andreas
dc.contributor.authorCzech, Christian
dc.contributor.authorDukart, Juergen
dc.contributor.authorGalasko, Douglas
dc.contributor.authorForoud, Tatiana
dc.contributor.authorChahine, Lana M.
dc.contributor.authorCoffey, Christopher S.
dc.contributor.authorSimuni, Tanya
dc.contributor.authorWeintraub, Daniel
dc.contributor.authorSeibyl, John
dc.contributor.authorPoston, Kathleen L.
dc.contributor.authorToga, Arthur W.
dc.contributor.authorTanner, Caroline M.
dc.contributor.authorMarek, Kenneth
dc.contributor.authorHutten, Samantha J.
dc.contributor.authorDziadek, Sebastian
dc.contributor.authorTrenkwalder, Claudia
dc.contributor.authorPagano, Gennaro
dc.contributor.authorMollenhauer, Brit
dc.contributor.departmentMedical and Molecular Genetics, School of Medicineen_US
dc.date.accessioned2023-03-13T11:59:13Z
dc.date.available2023-03-13T11:59:13Z
dc.date.issued2021-08
dc.description.abstractBackground: Cerebrospinal fluid (CSF) levels of monoamine metabolites may represent biomarkers of Parkinson's disease (PD). Objective: The aim of this study was quantification of multiple metabolites in CSF from PD versus healthy control subjects (HCs), including longitudinal analysis. Methods: Absolute levels of multiple monoamine metabolites in CSF were quantified by liquid chromatography coupled with tandem mass spectrometry from 161 individuals with early PD and 115 HCs from the Parkinson's Progression Marker Initiative and de novo PD (DeNoPA) studies. Results: Baseline levels of homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were lower in individuals with PD compared with HCs. HVA levels correlated with Movement Disorder Society Unified Parkinson's Disease Rating Scale total scores (P < 0.01). Both HVA/dopamine and DOPAC/dopamine levels correlated with caudate nucleus and raw DOPAC with putamen dopamine transporter single-photon emission computed tomography uptake ratios (P < 0.01). No metabolite changed over 2 years in drug-naive individuals, but some changed on starting levodopa treatment. Conclusions: HVA and DOPAC CSF levels mirrored nigrostriatal pathway damage, confirming the central role of dopaminergic degeneration in early PD.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationKremer T, Taylor KI, Siebourg-Polster J, et al. Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease. Mov Disord. 2021;36(8):1972-1978. doi:10.1002/mds.28608en_US
dc.identifier.urihttps://hdl.handle.net/1805/31841
dc.language.isoen_USen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1002/mds.28608en_US
dc.relation.journalMovement Disordersen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourcePMCen_US
dc.subjectMonoamine metabolitesen_US
dc.subjectCatecholamineen_US
dc.subjectNeurotransmitteren_US
dc.subjectBiomarkeren_US
dc.subjectParkinson's diseaseen_US
dc.subjectCSFen_US
dc.subjectHomovanillic aciden_US
dc.titleLongitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Diseaseen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
MDS-36-1972.pdf
Size:
343.59 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Medical and Molecular Genetics Works